Navigation Links
Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
Date:9/20/2011

negative cash flows from operating activities of approximately $63.0 million and $48.9 million, respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At June 30, 2011, the Company had cash and cash equivalents of approximately $3.5 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activities and plan of operations after October 31, 2011 and to repay the promissory notes issued in December 2010 as of said date. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations.  The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for the treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information regarding factors which could cause res
    '/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Neurologix Announces Second Quarter 2011 Financial Results
    2. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
    3. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
    4. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
    5. Creabilis Appoints Dr David Roblin as Chief Medical Officer
    6. MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science
    7. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
    8. Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors
    9. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
    10. Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
    11. Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2015)... ... July 24, 2015 , ... ... solution, indispensable to any modern scientific or pharmaceutical laboratory. FreezerPro® is an ... Users know precisely where a sample is located even before opening the ...
    (Date:7/23/2015)... ... , ... One hundred years ago this year, 18 model airplane clubs competed ... of winning the Henry S. Villard Trophy. The Academy of Model Aeronautics has plans ... to build a Free Flight fantasy club worthy of taking home the Villard Trophy. ...
    (Date:7/23/2015)... , July 23, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... an Investigational New Drug (IND) Application with the ... clinical testing of BHV-0223. Portage holds 54% equity ... BHV-0223 is a glutamate modulating agent and Biohaven ...
    (Date:7/23/2015)... (PRWEB) , ... July 23, 2015 , ... Global ... cell research in Santiago, Chile. The symposium will feature some of the world’s ... full day of high-level scientific discussion for medical professionals in general practice. , The ...
    Breaking Biology Technology:RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 2RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 4Academy of Model Aeronautics to Start Online Fantasy Flight Competition 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 4Global Stem Cells Group Announces Plans to Hold International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 3-4, 2015 2Global Stem Cells Group Announces Plans to Hold International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 3-4, 2015 3
    ... 2011 Oligomerix, Inc. presented results at the ... demonstrated that tau protein forms neurotoxic oligomers with ... results in tau,s self-fragmentation and in the degradation ... neurotoxic mode-of-action. Furthermore, certain tau oligomer species that ...
    ... RESTON, Virginia and BRNO, Czech Republic, November 16, ... Institute (MMCI) provides complete diagnostics, treatment, and ... and international patients. MMCI is the only health ... a member of the OECI (Organisation of European ...
    ... Livestream Info ... http://thehill.com/video/in-the-news/193083-livestreaming-genetic-testing-briefing . , Twitter: ... redefining cancer treatment, and the pace of discovery promises new ... That will be among the topics of discussion today at ...
    Cached Biology Technology:A New Mechanism for Tau Protein Pathology in Alzheimer's Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting 2Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS 2Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS 3Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer 2
    (Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
    (Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
    (Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
    Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
    ... people breathe while walking in the park, working in the ... spike their blood pressure, a new study suggests. Cardiovascular ... first to report a direct link between air pollution and ... results from these animal studies hold up, this could be ...
    ... time, next-generation DNA sequencing technologies have been turned on ... each year. The results will help to improve diagnosis, ... new strategies for vaccination. The study sets a ... a disease-causing bacterium: it is the first study of ...
    ... expectancy for patients with human immunodeficiency virus (HIV) has ... 1990s thanks to advancements in antiretroviral therapy, according to ... and Simon Fraser University in Vancouver, British Columbia. ... drop in AIDS deaths among 43,355 HIV-positive study participants ...
    Cached Biology News:OSU study shows exposure to bad air raises blood pressure 2OSU study shows exposure to bad air raises blood pressure 3Defining DNA differences to track and tackle typhoid 2Defining DNA differences to track and tackle typhoid 3Anti-HIV therapy boosts life expectancy more than 13 years 2
    BD BioCoat Collagen IV 150 mm Culture Dishes...
    Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
    MAb to Desmoplakin I & II Desmoplakin I & II...
    ... PI is used in conjuction with ... in the earlier stages of apoptosis (Annexin ... are in later stages of apoptosis or ... PI is detected in the orange range ...
    Biology Products: